Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study

Nephron - Clinical Practice

Volumn 118, Issue 2, 2011, Pages

  Nielsen, Stine Elkjaer ^a   Hansen, Henrik Post ^a   Jensen, Berit Ruud ^a   Parving, Hans Henrik ^b,c   Rossing, Peter ^a  

^a STENO DIABETES CENTER   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Biomarker; Diabetes mellitus; Diabetic nephropathy; Neutrophil gelatinase associated lipocalin; Tubular damage

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; ARTICLE; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN RESTRICTION; RETROSPECTIVE STUDY;

ACUTE-PHASE PROTEINS; ADULT; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOCALINS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS;

EID: 78650039536     PISSN: 16602110     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000320615     Document Type: Article

References (19)

1. Parving HH, Mauer M, Ritz E: Diabetic nephropathy; in Brenner BM (ed): Brenner & Rector's The Kidney, ed 8. Boston, Saunders, 2008, pp 1265-1298.
2. Parving HH, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P: Benefits of longterm antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996; 49: 1778-1782.
3. Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C: Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294: 1782-1787.
4. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637.
5. Cowland JB, Sorensen OE, Sehested M, Borregaard N: Neutrophil gelatinase-associated lipocalin is upregulated in human epithelial cells by IL-1, but not by TNF-. J Immunol 2003; 171: 6630-6639.
6. Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M, Hansen PR, Parving HH, Rossing P: Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Ned 2010;27:1144-1150.
7. Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P: Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 2010; 33: 1320-1324.
8. Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P: Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009; 32: 1684-1688.
9. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M: Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 337-344.
10. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, Buemi M: Neutrophil gelatinase-associated lipocalin as a marker of kidney damage. Am J Kidney Dis 2008; 52: 595-605.
11. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH: Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62: 220- 228.
12. Wagener G, Lee HT: In reply to 'Instability of urinary NGAL during long-term storage' and 'NGAL and cardiac surgery-associated acute kidney injury'. Am J Kidney Dis 2009; 53: 566.
13. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637.
14. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, Buemi M: Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009; 32: 91-98.
15. Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY: Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine 2009; 36: 45-51.
16. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Yoshioka T, Ogawa Y, Imamaki H, Kusakabe T, Ebihara K, Omata M, Satoh N, Sugawara A, Barasch J, Nakao K: Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009; 75: 285-294.
17. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004; 24: 307-315.
18. Haase M, Bellomo R, Devarajan P, Ma Q, Bennett MR, Mockel M, Matalanis G, Dragun D, Haase-Fielitz A: Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg 2009; 88: 124-130.
19. Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M: Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res 2009; 12: 7-14.